Scarica l'app Stockscreener
6.01
2.91%
0.17
Dopo l'orario di chiusura:
6.01
Precedente Chiudi:
$5.84
Aprire:
$5.81
Volume 24 ore:
31,149
Relative Volume:
0.21
Capitalizzazione di mercato:
$306.38M
Reddito:
-
Utile/perdita netta:
$-103.21M
Rapporto P/E:
-1.3065
EPS:
-4.6001
Flusso di cassa netto:
$-26.70M
1 W Prestazione:
-4.45%
1M Prestazione:
-13.28%
6M Prestazione:
-7.82%
1 anno Prestazione:
-62.18%
Intervallo 1D:
$5.6083
$6.05
Intervallo di 1 settimana:
$5.42
$6.40
Portata 52W:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Nome
Engene Holdings Inc
Settore
Industria
Telefono
(514) 332-4888
Indirizzo
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Confronta ENGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
6.01 | 306.38M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Iniziato | Piper Sandler | Overweight |
| 2025-02-14 | Downgrade | UBS | Buy → Neutral |
| 2024-12-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-27 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2024-04-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-03-28 | Iniziato | UBS | Buy |
| 2024-03-08 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Engene Holdings Inc Borsa (ENGN) Ultime notizie
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company - ACCESS Newswire
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch (NASDAQ:ENGN) - Seeking Alpha
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
(ENGN) On The My Stocks Page - Stock Traders Daily
Vontobel Holding Ltd. Makes New $69,000 Investment in enGene Holdings Inc. (NASDAQ:ENGN) - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
enGene Holdings GAAP EPS of -$0.38 - MSN
New Strong Buy Stocks for February 19th - Zacks Investment Research
enGene (NASDAQ:ENGN) Now Covered by Piper Sandler - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages - Defense World
Piper Sandler sets $26 target on Engene shares with Overweight rating - Investing.com Australia
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market - TipRanks
Piper Sandler Initiates Coverage on enGene Holdings With Overweight Rating, $26 Price Target - Marketscreener.com
Piper Sandler sets $26 target on Engene shares with Overweight rating By Investing.com - Investing.com South Africa
Analyzing Ratios: enGene Holdings Inc (ENGN)’s Financial Story Unveiled - The Dwinnex
enGene (NASDAQ:ENGN) Stock Rating Lowered by UBS Group - Defense World
enGene (NASDAQ:ENGN) Downgraded to Neutral Rating by UBS Group - MarketBeat
Sector Update: Health Care -February 14, 2025 at 03:41 pm EST - Marketscreener.com
EnGene Holdings Shares Fall After UBS Downgrade -February 14, 2025 at 02:55 pm EST - Marketscreener.com
UBS Downgrades enGene Holdings to Neutral From Buy, Cuts Price Target to $7 From $34 - Marketscreener.com
enGene downgraded to Neutral from Buy at UBS - TipRanks
(ENGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
enGene Holdings Inc (ENGN) vs. Its Peers: A Comparison - The News Heater
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Where are the Opportunities in (ENGN) - Stock Traders Daily
Cancer Biotech enGene Strengthens Team with $1.9M Equity Package as Bladder Cancer Trial Advances - StockTitan
ENGNenGene Holdings Inc. Latest Stock News & Market Updates - StockTitan
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) - Business Wire
FY2026 EPS Estimates for enGene Boosted by Leerink Partnrs - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts - Defense World
Leerink Partnrs Brokers Lift Earnings Estimates for enGene - MarketBeat
FY2029 EPS Estimates for enGene Reduced by Leerink Partnrs - MarketBeat
enGene Announces Oversubscribed $200 Million Private Placement F - GuruFocus.com
(ENGN) Proactive Strategies - Stock Traders Daily
Insider Returns Down To US$14k As enGene Holdings' Stock Dips 11% - Simply Wall St
How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77% - MSN
(ENGN) Trading Report - Stock Traders Daily
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why - MSN
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Analysts - Defense World
(ENGN) Technical Pivots with Risk Controls - Stock Traders Daily
enGene Holdings Awards Stock Options to New Employees in Key Talent Acquisition Move | ENGN Stock News - StockTitan
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 93.4% in December - MarketBeat
Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles - MSN
HC Wainwright Forecasts enGene’s Q1 Earnings (NASDAQ:ENGN) - Defense World
What is HC Wainwright's Estimate for enGene Q1 Earnings? - MarketBeat
Engene shares initiated at Buy as promising detalimogene data positions it ahead of recent approvals - Investing.com Nigeria
enGene (NASDAQ:ENGN) Receives “Market Outperform” Rating from JMP Securities - Defense World
Engene Holdings Inc Azioni (ENGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Engene Holdings Inc Azioni (ENGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 08 '24 |
Buy |
6.60 |
800 |
5,278 |
2,470,633 |
| Cooper Ronald Harold Wilfred | Chief Executive Officer |
Sep 27 '24 |
Buy |
5.70 |
10,000 |
57,000 |
10,000 |
| Glickman Richard M | Director |
May 28 '24 |
Option Exercise |
0.89 |
120 |
107 |
24,675 |
0.22%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):